Sodium-glucose cotransporter 2 inhibitors for chronic kidney disease: Why, when and when not

BACKGROUND: Chronic kidney disease (CKD) is a significant healthcare problem. More advanced stages are associated with increased mortality, morbidity and cost. Instigating measures to slow down disease progression at an early stage can save lives, and millions of dollars of taxpayers' money. OBJECTIVE: This article aims to provide evidence-based information to general practitioners, aiding the decision to initiate sodium-glucose cotransporter 2 (SGLT2) inhibitors for CKD patients in their day-to-day practice. DISCUSSION: SGLT2 inhibitors have emerged as a promising and safe addition to the renin-angiotensin-aldosterone system blockers for managing CKD. Randomised controlled trials have shown that SGLT2 inhibitors effectively slow CKD progression in both early and more advanced disease stages, regardless of diabetes status. SGLT2 inhibitors can be a valuable additional treatment option for CKD management in primary care and should be considered for most CKD patients.